On a preliminary basis, Zimmer Biomet Holdings (NYSE:ZBH)
estimates Q1 revenue to be down 9.5 – 10.5% from a year ago due to
declines in elective procedures amid COVID-19, headwinds that, it says,
will continue in Q2.
On the working capital front, at the end of 2019 it had $618M in cash and $1.5B available under its credit revolver.
2020 guidance withdrawn.
Final results will be released on May 11.
https://seekingalpha.com/news/3558772-zimmer-biomet-withdraws-guidance-due-to-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.